Washington University scientists, in collaboration with C2N Diagnostics, showed that the protein tau increases in blood after peripheral administration of an anti-tau antibody.
The study in mice found that the level of tau increase in blood correlated with the tau pathology in the brain.
C2N Diagnostics, LLC based St Louis, Missouri has developed technology platforms like the Stable Isotope Spike Absolute Quantitation (SISAQ) and Stable Isotope Labeling Kinetic (SILK) that enable the measurement of the absolute concentration of peptides and specific proteins in both CSF and plasma.
“We focus on a variety of assays – using the primary platform of mass spectrometry – to quantitate proteins and other biomolecules implicated in neurodegeneration,” said Joel B. Braunstein, MD, CEO, C2N Diagnostics.
These assays are currently available for use in preclinical research and clinical research drug development settings. Some of these assays may be used in the future to serve as a clinical diagnostic aid in the detection and monitoring of pathways implicated in Alzheimer’s disease and other forms of neurodegeneration, he added.